These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 642029)

  • 1. Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 May; 60(5):1107-11. PubMed ID: 642029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.
    Lubet RA; Carlson DE
    J Natl Cancer Inst; 1978 Sep; 61(3):897-903. PubMed ID: 278867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
    Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
    Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.
    Adler A; Altbaum I
    J Natl Cancer Inst; 1982 Jun; 68(6):963-9. PubMed ID: 6953275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against MOPC-315 plasmacytoma by immunization with C-type particle preparations.
    Kleinman R; Dray S
    Cancer Res; 1978 Jan; 38(1):223-5. PubMed ID: 201375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
    Barker E; Mokyr MB
    Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
    Barker E; Mokyr MB
    Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular changes and antitumor responses in the plasmacytoma-bearing mouse following cyclophosphamide treatment.
    Shanahan TC; Ceglowski WS; Havas HF
    Cancer Res; 1985 Dec; 45(12 Pt 1):6463-70. PubMed ID: 2866030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of tumor-specific cytotoxic CD8+ T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy.
    Takesue BY; Pyle JM; Mokyr MB
    Cancer Res; 1990 Dec; 50(23):7641-9. PubMed ID: 2123740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune RNA-mediated transfer of tumor antigen responsiveness to unresponsive peritoneal exudate cells from tumor-bearing animals.
    Braun DP; Dray S
    Cancer Res; 1977 Nov; 37(11):4138-44. PubMed ID: 908048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor-bearing mice.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1980 Jul; 40(7):2135-41. PubMed ID: 6446379
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.
    Adler A; Keisari Y; Ofir R
    J Natl Cancer Inst; 1985 Feb; 74(2):429-36. PubMed ID: 3856051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Barker E; Weiskirch LM; Takesue BY; Pyle JM
    Cancer Res; 1989 Aug; 49(16):4597-606. PubMed ID: 2568174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
    Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
    J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a cooperative group human myeloma protocol using the MOPC 104E myeloma model.
    Hiramoto R; Ghanta V; Durant JR
    Cancer Res; 1975 May; 35(5):1309-13. PubMed ID: 1120314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
    Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
    J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.